English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/59519
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

AuthorsSantamaría, Carlos; Chillón, M. del Carmen; García-Sanz, Ramón; Caballero, Maria Dolores; Mateos, Maria Victoria; Sarasquete, María Eugenia; Díaz-Mediavilla, J.; San Miguel, Jesús F. ; González, Marcos
Issue Date2010
CitationAnnals of Hematology 89(5): 453-458 (2010)
AbstractWe have analyzed brain and acute leukemia, cytoplasmic (BAALC) gene expression and other genetic markers (ERG, EVI1, MN1, PRAME, WT1, FLT3, and NPM1 mutations) in 127 intermediate-risk acute myeloid leukemia (AML) patients: 98 cytogenetically normal and 29 with intermediate-risk cytogenetic alterations. High versus low BAALC expressers showed a higher refractoriness to induction treatment (31% vs 10%; p∈=∈.005), lower complete remission rate after salvage therapy (82% vs 97%; p∈=∈.010), and lower 3-year overall (23% vs 58%, p∈<∈.001) and relapse-free survival (26% vs 52%, p∈=∈.006). Similar results were found when cytogenetic subgroups were analyzed separately. Multivariate models confirmed the unfavorable prognosis of this marker. In conclusion, BAALC is a relevant prognostic marker in intermediate-risk AML. © 2009 Springer-Verlag.
Identifiersdoi: 10.1007/s00277-009-0864-x
issn: 0939-5555
e-issn: 1432-0584
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.